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For time-to-event data with finitely many competing risks, the
proportional hazards model has been a popular tool for relating the
cause-specific outcomes to covariates [Prentice et al. Biometrics 34
(1978) 541–554]. This article studies an extension of this approach to
allow a continuum of competing risks, in which the cause of failure
is replaced by a continuous mark only observed at the failure time.
We develop inference for the proportional hazards model in which the
regression parameters depend nonparametrically on the mark and the
baseline hazard depends nonparametrically on both time and mark.
This work is motivated by the need to assess HIV vaccine efficacy,
while taking into account the genetic divergence of infecting HIV
viruses in trial participants from the HIV strain that is contained in
the vaccine, and adjusting for covariate effects. Mark-specific vaccine
efficacy is expressed in terms of one of the regression functions in
the mark-specific proportional hazards model. The new approach is
evaluated in simulations and applied to the first HIV vaccine efficacy
trial.
1. Introduction. It has been 30 years since Prentice et al. [14] intro-
duced a Cox regression framework for the analysis of failure time data in
the presence of finitely many competing risks. Yet many important appli-
cations of competing risks methodology involve continuous causes-of-failure
(marks). In HIV vaccine trials, for example, genetic divergence of infecting
Received December 2006; revised September 2007.
1Supported in part by NSF Grant DMS-0604576, NIH Grant 2 RO1 AI054165-04 and
funds provided by the University of North Carolina at Charlotte.
2Supported in part by NIH Grant 2 RO1 AI054165-04.
3Supported in part by NSF Grant DMS-0505201.
AMS 2000 subject classifications. Primary 62N01; secondary 62N02, 62N03, 62G20.
Key words and phrases. Competing risks, distribution-free confidence bands and tests,
failure time data, genetic data, HIV vaccine trial, pointwise and simultaneous confidence
bands, semiparametric model, survival analysis.
This is an electronic reprint of the original article published by the
Institute of Mathematical Statistics in The Annals of Statistics,
2009, Vol. 37, No. 1, 394–426. This reprint differs from the original in pagination
and typographic detail.
1
2 Y. SUN, P. B. GILBERT AND I. W. MCKEAGUE
HIV viruses from the HIV strain represented in the vaccine needs to be
taken into account to properly assess vaccine efficacy, but the mark variable
is essentially continuous because of the large number of mutations involved.
Other examples of continuous mark variables include lifetime medical cost
or a quality of life score associated with survival time [13]. The grouping
of continuous mark data into discrete marks is unsatisfactory because that
amounts to a coarsening of the data and the results will depend on the way
the groups are defined. To address this problem, we develop inference for a
proportional hazards model in which both the regression parameters and the
baseline hazard function depend nonparametrically on a continuous mark.
The paper is motivated by the need for new methods to analyze data
from HIV vaccine efficacy trials. Approximately 15,000 new HIV infections
occur each day [20], making development of a protective HIV vaccine a top
priority for biomedical science. In efficacy trials thousands of HIV-negative
volunteers are randomized to receive vaccine or placebo, and are monitored
for HIV infection. Five efficacy trials have recently been conducted. A pri-
mary objective of each trial is to assess vaccine efficacy (VE) to prevent
infection, where typically VE is defined as one minus the hazard ratio (vac-
cine/placebo) of HIV infection. One of the greatest barriers to achieving
an efficacious vaccine is the extreme genetic heterogeneity of HIV [6, 11].
Although it may be possible to develop a vaccine that protects against HIV
strains genetically similar to the HIV virus or viruses represented in the vac-
cine, it may be quite difficult to develop one to protect against HIV strains
dissimilar from the vaccine material. This phenomenon is well known for
flu vaccines—moderate genetic mismatch between an exposing flu virus and
the virus represented in the vaccine causes vaccine failure, which has necessi-
tated development of a new vaccine each year that is closely matched to the
contemporary circulating flu strains. The genetic divergence (or distance)
between two aligned HIV sequences can be measured as the weighted per-
cent mismatch of amino acids, and since this distance may be unique for all
infected subjects, it is natural to consider it as a continuous mark variable.
The formidable problem of HIV genetic diversity implies that an important
objective of an efficacy trial is assessment of if and how VE depends on the
genetic divergence.
This problem can be addressed in terms of the conditional mark-specific
hazard function, defined as
λ(t, v|z) = lim
h1,h2→0
P{T ∈ [t, t+ h1),
(1)
V ∈ [v, v+ h2)|T ≥ t,Z(t) = z}/h1h2,
where T is the failure (infection diagnosis) time, V is a continuous mark vari-
able and Z(t) is a (possibly time-dependent) p-dimensional covariate. Huang
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and Louis [7] developed the nonparametric maximum likelihood estimator of
the joint distribution of T and V in terms of the unconditional mark-specific
hazard function. Gilbert, McKeague and Sun [5] defined mark-specific vac-
cine efficacy as VE(t, v) = 1− λ(t, v|1)/λ(t, v|0), with z being the indicator
of membership in the vaccine group; they developed several nonparametric
and semiparametric tests concerning VE(t, v).
In this article, we develop the mark-specific proportional hazards (PH)
model
λ(t, v|z(t)) = λ0(t, v) exp{β(v)T z(t)},(2)
where the baseline hazard function λ0(·, v) and the p-dimensional regression
parameter β(v) are unknown continuous functions of v. As far as we know,
this model has never been studied in the literature, even though it is closely
related to the discrete cause-of-failure models discussed by Prentice et al.
[14]. The approach in the continuous case departs from the discrete case in
that it is necessary to “borrow strength” from data in a neighborhood of v,
with the data closest to v contributing the most.
For the HIV vaccine trial application, we partition the covariate as z(t) =
(z1, z2(t))
T , where z1 is the treatment (vaccine) group indicator and z2(t)
is a vector of possibly time-dependent covariates. Then the vaccine efficacy
defined above takes the simpler form VE(v) = 1− exp(β1(v)), without any
dependence on t. By assuming proportional hazards, model (2) can provide
more powerful tests of mark-specific vaccine efficacy than the nonparamet-
ric procedures of Gilbert, McKeague and Sun [5], and the model allows
adjustment for covariate effects. Furthermore, ignoring the mark variable
and studying vaccine efficacy using the standard Cox model, as is widely
practiced in vaccine trials for many infectious diseases, can give misleading
results. In fact, even in the case of model (2) with z as the treatment in-
dicator, the ordinary (marginal) Cox model will be misspecified unless the
baseline λ0(t, v) factors into separate functions of t and v.
Indeed, consider the model λ(t, v|z = 0) = γ0/2 + γ1tv and λ(t, v|z = 1) =
γ0v + γ1tv
2, for t ≥ 0, 0 ≤ v ≤ 1, z ∈ {0,1}. The corresponding marginal
hazard functions are λ(t|z = 0) = γ0/2+γ1t/2 and λ(t|z = 1) = γ0/2+γ1t/3,
for t≥ 0. It is clear that λ(t|z) is not a proportional hazards model unless γ0
or γ1 is zero. If γ1 = 0, the resulting marginal hazards become proportional
for z = 0 and z = 1. However, in this example, the marginal vaccine efficacy
VE= 1−λ(t|z = 1)/λ(t|z = 0) = 0 while the mark-specific vaccine efficacy is
VE(v) = 1− 2v. The ordinary Cox model averages the mark-specific vaccine
efficacy over its range, and important vaccine effects may be missed. This
issue will be further illustrated in our simulation study. In general, use of
the ordinary Cox model for studying hazard ratios can be misleading if an
important mark variable is ignored. The mark-specific PH model offers a
way to correct for that deficiency.
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We also consider a cumulative vaccine efficacy estimand defined as CV(v) =∫ v
a VE(u)du where a > 0. We develop distribution-free uniform confidence
bands for CV(v), which are useful for inferential purposes. In addition we
derive test statistics for evaluating mark-specific vaccine efficacy based on
the estimator of CV(v).
The paper is organized as follows. Section 2 develops a local partial likeli-
hood procedure for estimating β(v), leading to the construction of pointwise
confidence intervals and formal tests for various hypotheses of interest con-
cerning vaccine efficacy. A simulation study evaluating the performance of
the proposed tests and the pointwise and simultaneous confidence inter-
vals for VE(v) and CV(v) is presented in Section 3. The proposed methods
are applied to analyze the data from the first HIV vaccine efficacy trial in
Section 4. We discuss some general aspects of mark-specific PH models in
Section 5. Proofs of the main results are placed in the Appendix.
2. Mark-specific proportional hazards model.
2.1. Local partial likelihood. We begin by stating some assumptions and
notations that are used throughout the paper. The mark variable V is as-
sumed to have a known and bounded support; rescaling V if necessary,
this support is taken without loss of generality to be [0,1]. The obser-
vations (Xi, δi, δiVi,Zi), i = 1, . . . , n, are assumed to be i.i.d. replicates of
(X,δ, δV,Z), where X is the right-censored failure time corresponding to
T , which satisfies the model (2), and δ is the indicator of non-censorship.
The mark is assumed to be observed whenever the corresponding failure
time is uncensored; when δi = 0, Vi is undefined and is not meaningful.
The censoring time is assumed to be conditionally independent of (T,V )
given Z.
We consider a localized version of the log partial likelihood function for
β = β(v) at a fixed v:
l(v,β) =
n∑
i=1
∫ 1
0
∫ τ
0
Kh(u− v)
[
βTZi(t)− log
(
n∑
j=1
Yj(t)e
βTZj(t)
)]
(3)
×Ni(dt, du),
where Kh(x) =K(x/h)/h, K(·) is a kernel function with support [−1,1], τ
is the end of the follow-up period and h= hn is a bandwidth. Here Yi(t) =
I(Xi ≥ t) and Ni(t, v) = I(Xi ≤ t, δi = 1, Vi ≤ v) is the marked point counting
process with a jump at an uncensored failure times Xi and the associated
mark Vi. For background on marked point processes see Bre´maud [2] and
Martinussen and Scheike [10].
The log partial likelihood function (3) resembles that of Kalbfleisch and
Prentice [8] in the case of discrete marks, except that it borrows strength
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from observations having marks in the neighborhood of v. The kernel func-
tion is designed to give greater weight to observations with marks near v
than those further away. The local maximum partial likelihood estimator of
β(v) is a maximizer βˆ(v) of (3). A similar approach has been studied by
Cai and Sun [3] for estimating time-dependent coefficients in Cox regression
models.
Denote µj =
∫
ujK(u)du, νj =
∫
ujK2(u)du for j = 0,1,2. For β ∈ Rp,
t≥ 0, let
S(j)(t, β) = n−1
n∑
i=1
Yi(t) exp{βTZi(t)}Zi(t)⊗j ,
where for any z ∈ Rp, we denote z⊗0 = 1, z⊗1 = z and z⊗2 = zzT . Define
s(j)(t, β) =ES(j)(t, β) and
Jn(t, β) =
S(2)(t, β)
S(0)(t, β)
−
(
S(1)(t, β)
S(0)(t, β)
)⊗2
,
J(t, β) =
s(2)(t, β)
s(0)(t, β)
−
(
s(1)(t, β)
s(0)(t, β)
)⊗2
.
Taking the derivative of l(v,β) with respect to β gives the score function
U(v,β) = l′β(v,β)
(4)
=
n∑
i=1
∫ 1
0
∫ τ
0
Kh(u− v)
[
Zi(t)− S
(1)(t, β)
S(0)(t, β)
]
Ni(dt, du).
The maximum partial likelihood estimator is a solution to U(v, βˆ(v)) =
0, and can be computed using a Newton–Raphson algorithm. The second
derivative of l(v,β) with respect to β yields
l′′β(v,β) =−
n∑
i=1
∫ 1
0
∫ τ
0
Kh(u− v)Jn(t, β)Ni(dt, du).
Although inference on β is usually of primary interest, the baseline func-
tion λ0(t, v) can also be estimated, by smoothing the increments of the
following estimator of the doubly cumulative baseline function Λ0(t, v) =∫ t
0
∫ v
0 λ0(s,u)dsdu:
Λˆ0(t, v) =
∫ t
0
∫ v
0
N(ds, du)
nS(0)(s, βˆ(u))
.(5)
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2.2. Asymptotic results. We make use of the following regularity condi-
tions; not all of these conditions are required for the proof of each theorem,
nor are they the minimum required set of conditions.
Condition A.
(A.1) β(v) has componentwise continuous second derivatives on [0,1]. The
second partial derivative of λ0(t, v) with respect to v exists and is con-
tinuous on [0, τ ]× [0,1]. The covariate process Z(t) has paths that are
left-continuous and of bounded variation, and satisfies the moment
condition E[‖Z(t)‖4 exp(2M‖Z(t)‖)] < ∞, where M is a constant
such that (v,β(v)) ∈ [0,1]× (−M,M)p for all v and ‖A‖=maxk,l |akl|
for a matrix A= (akl).
(A.2) For j = 0,1,2, each component of s(j)(t, θ) is continuous on [0, τ ] ×
[−M,M ]p, and supt∈[0,τ ],θ∈[−M,M ]p ‖S(j)(t, θ)−s(j)(t, θ)‖=Op(n−1/2).
(A.3) s(0)(t, θ)> 0 on [0, τ ]× [−M,M ]p and the matrix Σ(v) = ∫ τ0 J(t, β(v))×
λ0(t, v)s
(0)(t, β(v))dt is positive definite.
(A.4) E(Ni(dt, dv)|Ft−) =E(Ni(dt, dv)|Yi(t),Zi(t)), where Ft = σ{I(Xi ≤ s,
δi = 1), I(Xi ≤ s, δi = 0), ViI(Xi ≤ s, δi = 1),Zi(s); 0≤ s≤ t, i= 1, . . . , n}
is the (right-continuous) filtration generated by {Ni(s, v), Yi(s), Zi(s); 0≤
s≤ t,0≤ v ≤ 1, i= 1, . . . , n}.
(A.5) The kernel function K(·) is symmetric with support [−1,1] and of
bounded variation. The bandwidth satisfies nh2→∞ and nh5→ 0 as
n→∞.
Note that the condition (A.2) holds under the condition (A.1) given some
additional moment conditions on Z(t)−Z(s) and exp(bTZ(t))−exp(bTZ(s)).
If Z(t) = Z, not depending on t, then (A.2) holds by the Donsker theorem
(Theorem 19.5 of van der Vaart [19]). The condition (A.4) assumes that
the mark-specific instantaneous failure rate at time t given the observed in-
formation up to time t only depends on the failure status and the current
covariate value. Under (A.4) and by the definition (1), E(Ni(dt, dv)|Ft−) =
Yi(t)λ(t, v|Zi(t))dt dv, andMi(t, v) =
∫ t
0
∫ v
0 [Ni(ds, dx)−Yi(s)λ(s,x|Zi(s))dsdx]
is a martingale with respect to Ft for each fixed v ([10], page 31). Further,
it follows by Aalan and Johansen [1] that Mi(·, v1) and Mi(·, v2)−Mi(·, v1)
are orthogonal square integrable martingales with respect to Ft for any 0≤
v1 ≤ v2 ≤ 1. To avoid the problems at the boundaries v = 0,1, we shall study
the asymptotic properties of βˆ(v) for the interior values of v ∈ [a, b]⊂ (0,1).
First we present the following result that is essential for proving the
asymptotic normality of βˆ(v) and provides insight into the constructions
of the confidence bands and test statistics that follow. Let
W˜A(v) = n
−1/2
n∑
i=1
∫ v
a
∫ τ
0
A(u)
[
Zi(t)− s
(1)(t, β(u))
s(0)(t, β(u))
]
Mi(dt, du),(6)
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where A(u) is a deterministic p× p matrix with bounded components and
0≤ a < b≤ 1.
Theorem 1. Assume that each component of the p × p matrix A(v),
v ∈ [a, b], is continuous. Under conditions (A.1)–(A.4), W˜A(v) converges
weakly to a p-dimensional mean-zero Gaussian martingale, WA(v), with con-
tinuous sample paths on v ∈ [a, b]. The covariance matrix of WA(v) is given
by Cov(WA(v)) =
∫ v
a A(u)Σ(u)A(u)du.
Let
ΣˆAˆ(v) = n
−1
n∑
i=1
∫ v
a
∫ τ
0
Aˆ(u)Jn(t, βˆ(u))Aˆ
T (u)Ni(dt, du),(7)
where Aˆ(v) is a consistent estimator of A(v) uniformly in v ∈ [a, b]⊂ [0,1].
It can be shown that ΣˆA(v) is a consistent estimator of Cov(WA(v)).
The consistency and asymptotic normality of βˆ(v) are established in the
next two theorems.
Theorem 2. Under conditions (A.1)–(A.5), βˆ(v) converges to β(v) uni-
formly in v ∈ [a, b]⊂ (0,1).
Theorem 3. Under conditions (A.1)–(A.5), (nh)1/2(βˆ(v) − β(v)) D−→
N(0, ν0Σ
−1(v)) for v ∈ [a, b].
The proof of Theorem 3 uses a Taylor expansion of the score function,
leading to βˆ(v)−β(v) =−(l′′β(v,β∗(v)))−1U(β(v)), where β∗(v) is on the line
segment between βˆ(v) and β(v). The asymptotic variance of n−1/2h1/2U(β(v))
is shown to be ν0Σ(v), which is the in probability limit of Σ˜n(β(v)) = n
−1h×∑n
i=1
∫ 1
0
∫ τ
0 (Kh(u−v))2Jn(t, β(v))Ni(dt, du). It can also be shown that Σˆ(v)≡
−l′′β(v, βˆ(v))/n P−→Σ(v) as n→∞. Thus, the asymptotic variance of (nh)1/2×
(βˆ(v)− β(v)) can be estimated by Σˆ1(v) = (l′′β(v, βˆ(v))/n)−1Σ˜n(βˆ(v))(l′′β(v,
βˆ(v))/n)−1. An alternative estimator is Σˆ2(v) =−ν0(l′′β(v, βˆ(v))/n)−1. It is
easy to check that ν0 = 3/5 for Epanechnikov’s kernel K(x) =
3
4(1 − x2),−1< x< 1. Simulations indicate that the two estimators have similar finite
sample performance.
Theorem 3 will lead to the construction of pointwise confidence intervals
for VE(v). Simultaneous inference over v ∈ [a, b] will be possible in terms
of the estimate Bˆ(v) =
∫ v
a βˆ(u)du of the cumulative regression coefficient
B(v) =
∫ v
a β(u)du. We have the following weak convergence result for Bˆ(v).
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Theorem 4. Under conditions (A.1)–(A.5), n1/2(Bˆ(v) − B(v)) con-
verges weakly to a p-dimensional mean-zero Gaussian martingale WΣ−1(v)
with continuous sample paths on v ∈ [a, b]. The covariance matrix ofWΣ−1(v)
is
∫ v
a Σ(u)
−1 du, which can be consistently estimated by ΣˆAˆ(v) defined by (7)
with A(v) = (Σ(v))−1 and Aˆ(v) = (Σˆ(v))−1.
2.3. Confidence bands for vaccine efficacy. Let β(v) = (β1(v), β
T
2 (v))
T .
Then the vaccine efficacy can be expressed as VE(v) = 1− exp(β1(v)). The
estimated vaccine efficacy is V̂E(v) = 1 − exp(βˆ1(v)). By Theorem 3 and
the delta method, (nh)1/2(V̂E(v)−VE(v)) D−→N(0, ν0σ21(v) exp(2β1(v))) for
v ∈ [a, b], where σ21(v) is the first element on the diagonal of Σ−1(v). Let
σˆ2β1(v) be the first element on the diagonal of Σˆ1(v). By the discussions
on the consistent estimators for the asymptotic variance following Theorem
3, σˆ2β1(v) is a consistent estimator for ν0σ
2
1(v). A pointwise 100(1 − α)%
confidence band for VE(v) is given by
V̂E(v)± (nh)−1/2zα/2σˆβ1(v) exp(βˆ1(v)), a≤ v ≤ b,(8)
where zα/2 is the upper α/2 quantile of the standard normal distribution.
To derive simultaneous confidence bands for the cumulative vaccine effi-
cacy CV(v) =
∫ v
a VE(u)du, we consider the point estimator ĈV(v) =∫ v
a V̂E(u)du. Then
√
n(ĈV(v)−CV(v)) =√n
∫ v
a
(exp(β1(v))− exp(βˆ1(v)))du.
Note that
√
n(ĈV(v) − CV(v)) ≈ √n ∫ va exp(β1(v)(β1(v) − βˆ1(v))du. From
the proof of Theorem 4, it can be shown that
√
n(ĈV(v)−CV(v)) converges
weakly to a mean-zero Gaussian process, eT1WA(v), a≤ v ≤ b, with continu-
ous paths and independent increments, where A(v) = exp(β1(v))Σ(v)
−1 and
e1 is the first column of the p× p identity matrix. The variance of eT1WA(v)
equals ρ2(v) =
∫ v
a σ
2
1(u) exp(2β1(u))du by Theorem 1, which can be conve-
niently estimated by
∫ v
a σˆ
2
1(u) exp(2βˆ1(u))du, where σˆ
2
1(v) is the first element
of the diagonal of Σˆ(v)−1. We suspect that this estimator may ignore the
finite sample correlations of β1(v)− βˆ1(v) at different values of v, thus over-
or underestimating the true variance. We propose to use ρˆ2(v) = eT1 ΣˆAˆ(v)e1
as the estimator of the asymptotic variance of
√
n(ĈV(v)−CV(v)), where
ΣˆAˆ(v) is obtained from (7) with Aˆ(v) = exp(βˆ1(v))Σˆ(v)
−1, which is uni-
formly consistent by Theorem 1. Consequently, a pointwise 100(1 − α)%
confidence band for CV(v) is given by
ĈV(v)± n−1/2zα/2ρˆ(v), a≤ v ≤ b.(9)
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Let V be a set of values of v in [a, b]. We may take V = [a, b] or V = {vk, k =
1, . . . ,K} with v1 < · · · < vK . Note that if U(v) is a Gaussian martingale
with variance ρ2(v), for a ≤ v ≤ b, then U(v)ρ(b)[ρ2(b) + ρ2(v)]−1 has the
same distribution as B0(ρ2(v)/(ρ2(b) + ρ2(v))), a ≤ v ≤ b, where B0(·) is
a Brownian bridge. By the weak convergence of
√
n(ĈV(v) − CV(v)), the
uniform consistency of ρˆ2(v) to ρ2(v) and the continuous mapping theorem,
we have
sup
v∈V
|√n(ĈV(v)−CV(v))ρˆ(b)/(ρˆ2(b) + ρˆ2(v))|
D−→ sup
v∈V
|B0(ρ2(v)/(ρ2(b) + ρ2(v)))|.
Thus a simultaneous 100(1−α)% confidence band for CV(v), v ∈ V , is given
by
ĈV(v)± n−1/2uα[ρˆ2(b) + ρˆ2(v)]/ρˆ(b),(10)
where uα is the upper α-quantile of the distribution of supv∈V |B0(ρ2(v)/
(ρ2(b) + ρ2(v)))|. The uα is the upper α-quantile of sup0≤v≤1/2 |B0(v)| if
V = [a, b], which has been tabulated by Schumacher [15] for some α values.
In the simulation study presented in the next section, we estimate uα by the
upper α-quantile of the distribution of supvk∈V |B0(ρˆ2(vk)/(ρˆ2(b) + ρˆ2(vk)))|
in both cases when V = [a, b] or V = {vk, k = 1, . . . ,K}, which can be ob-
tained by simulating a Brownian bridge for given ρˆ2(v).
Alternatively, other resampling techniques such as the Gaussian multiplier
method of Lin, Wei and Ying [9] can be used to estimate the critical value
uα. This method can be briefly outlined as follows. Let ξ1, . . . , ξn be i.i.d.
standard normal random variables and
W ∗
Aˆ
(v) = n−1/2
n∑
i=1
ξi
∫ v
0
∫ τ
0
Aˆ(u)
[
Zi(t)− S
(1)(t, βˆ(u))
S(0)(t, βˆ(u))
]
Mi(dt, du).(11)
Then the distribution
√
n(ĈV(v)−CV(v)) can be approximated by the con-
ditional distribution of eT1W
∗
Aˆ
(v) given the observed data sequence, where
Aˆ= exp(βˆ1(v))×(Σˆ(v))−1. Consequently, the distribution of supv∈V |
√
n(ĈV(v)−
CV(v))ρˆ(b)[ρˆ2(b)+ ρˆ2(v)]−1| can be approximated by the conditional distri-
bution of U∗ = supv∈V |eT1W ∗Aˆ(v)ρˆ(b)[ρˆ2(b) + ρˆ2(v)]−1| given the observed
data sequence. Let u∗α be the (1− α)-quantile of the copies of U∗ obtained
by repeatedly generating sets of i.i.d. standard normal random variables. A
simultaneous 100(1−α)% confidence band for CV(v), v ∈ V , is given by
ĈV(v)± n−1/2u∗α[ρˆ2(b) + ρˆ2(v)]/ρˆ(b).(12)
This resampling technique is also applicable to the hypothesis tests for vac-
cine efficacy developed in the next subsection.
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2.4. Testing vaccine efficacy. We are interested in testing the following
two sets of hypotheses. The first set of hypotheses is
H10 :VE(v) = 0 for v ∈ [a, b]
versus H1a :VE(v) 6= 0 for some v (general alternative)
or H1m :VE(v)≥ 0 with strict inequality for at least some v
(monotone alternative).
The second set of hypotheses is
H20 :VE(v) does not depend on v ∈ [a, b]
versus H2a :VE(v) depends on v (general alternative)
or H2m :VE(v) decreases as v increases (monotone alternative).
Let β1(v) be the first component of β(v). Then the null hypothesis H10 is
equivalent to β1(v) = 0 and the null hypothesis H20 is equivalent to β1(v)
does not depend on v. The null hypothesis H10 implies the vaccine affords
no protection against any infecting strain of virus. The alternative H1m in-
dicates that the vaccine provides protection for at least some of the infecting
strains, while H1a states that the vaccine provides either protection or in-
creased risk for some infecting strains. The null hypothesis H20 implies there
is no difference in vaccine effect for different infecting strains, measured by
their distance v to the strains contained in the vaccine. The ordered alter-
native H2m states that vaccine efficacy decreases with v and the alternative
H2a indicates that the vaccine efficacy changes with v.
In this section, we develop some test procedures for detecting departures
from H10 in the direction of H1m and H1a and for detecting departures
from H20 in the direction of H2m and H2a. By Theorem 4 and the discus-
sions in Section 2.3, the process
√
n(ĈV(v)−CV(v)), a≤ v ≤ b, converges
weakly to a Gaussian martingale with predictable variation ρ2(v). Let ξ(v) =√
n(ĈV(v)−CV(v))/ρ(b). It follows from Theorem 4 that ξ(v) D−→W (t(v)),
a≤ v ≤ b, where W (·) is a Wiener process and t(v) = ρ2(v)/ρ2(b).
To test H10, let Zˆ
(1)(v) =
√
nĈV(v)/ρˆ(b) and tˆ(v) = ρˆ2(v)/ρˆ2(b). Consider
the following test statistics:
T (1)a =
∫ b
a
(Zˆ(1)(v))2 dtˆ(v), T
(1)
m1 =
∫ b
a
Zˆ(1)(v)dtˆ(v).
These test statistics have somewhat complicated null distributions (see be-
low) so we also consider the following simpler test statistic based on a finite
grid, which leads to a standard normal null distribution:
T
(1)
m2 = (K − 1)−1/2
K∑
k=2
(Zˆ(1)(vk)− Zˆ(1)(vk−1))/(tˆ(vk)− tˆ(vk−1))1/2,
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where a≤ v1 < · · ·< vK ≤ b are the grid points in [a, b]. A similar test statis-
tic with a standard normal null distribution is also proposed for H20 later.
Under H10, T
(1)
a
D−→ ∫ ba (W (t(v)))2 dt(v) D= ∫ 10 (W (t))2 dt, T (1)m1 D−→∫ b
a W (t(v))dt(v)
D
=
∫ 1
0 W (t)dt and T
(1)
m2
D−→N(0,1). The distributions of T (1)a
and T
(1)
m1 under H10 can also be approximated by those of
∫ b
a (W (tˆ(v)))
2 dtˆ(v)
and
∫ b
a W (tˆ(v))dtˆ(v) for given tˆ(v), respectively, which are used in the nu-
merical studies for better finite sample approximations. We denote the upper
α-quantiles of these two distributions by c
(1)
a and c
(1)
m1, respectively.
The test statistic T
(1)
a captures general departures H1a, while the test
statistics T
(1)
m1 and T
(1)
m2 are sensitive to the monotone departure H1m. Both
test statistics T
(1)
m1 and T
(1)
m2 are likely to be positive when VE(v)≥ 0 for all
v with strict inequality for some v. Hence the tests based on T
(1)
a , T
(1)
m1 and
T
(1)
m2 reject H10 if T
(1)
a > c
(1)
a , T
(1)
m1 > c
(1)
m1 and T
(1)
m2 > zα, respectively.
To test H20, let Zˆ
(2)(v) =
√
n( 1v−a ĈV(v) − 1b−aĈV(b))/ρˆ(b). Note that,
under H20, Zˆ
(2)(v) =
√
n[ 1v−a(ĈV(v)−CV(v))− 1b−a(ĈV(b)−CV(b))]/ρˆ(b).
By Theorem 4 and the continuous mapping theorem, under H20, Zˆ
(2)(v)
D−→
1
v−aW (t(v))− 1b−aW (1) ≡ Z(2)(v) for v ∈ [a1, b], where a < a1 < b. We pro-
pose the following test statistics for evaluating H20:
T (2)a =
∫ b
a1
(Zˆ(2)(v))2 dtˆ(v), T
(2)
m1 =
∫ b
a1
Zˆ(2)(v)dtˆ(v),
T
(2)
m2 = Πˆ
−1
K
K∑
k=2
(Zˆ(2)(vk−1)− Zˆ(2)(vk))/pˆik,
where a1 ≤ v1 < · · ·< vK ≤ b are K grid points in [a1, b], pˆi2k is an estimate of
the variance pi2k = Var(Z
(2)(vk−1)− Z(2)(vk)) and Πˆ2K is an estimate of the
variance Π2K of
∑K
k=2(Z
(2)(vk−1)− Z(2)(vk))/pik . By the covariance of the
Wiener process, it is easy to show that
τi,j =Cov(Z
(2)(vi),Z
(2)(vj))
=
t(vi)
(vi − a)(vj − a) −
t(vi)
(vi − a)(b− a) −
t(vj)
(vj − a)(b− a) +
1
(b− a)2 ,
for vi ≤ vj . Thus, pi2k = τk−1,k−1− 2τk−1,k + τk,k. Let Γ = (τi,j)K×K and
ξT = (pi−12 , pi
−1
3 − pi−12 , . . . , pi−1K − pi−1K−1,−pi−1K ).
It follows that ΠK = ξ
TΓξ. The estimates pˆi2k and Πˆ
2
K are obtained by re-
placing t(v) with tˆ(v).
By the weak convergence of Zˆ(2)(v) to Z(2)(v), and the convergence in
probability of tˆ(v) to t(v), a1 ≤ v ≤ b, we have T (2)m2 D−→N(0,1) under H20. It
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also follows that T
(2)
a
D−→ ∫ ba1(Z(2)(v))2 dt(v), and T (2)m1 D−→ ∫ ba1 Z(2)(v)dt(v)
under H20. The distributions of T
(2)
a and T
(2)
m1 under H20 can be approxi-
mated by those of
∫ b
a1
(W (tˆ(v))/(v − a) − W (tˆ(b))/(b − a))2 dtˆ(v) and∫ b
a1
(W (tˆ(v))/(v − a) − W (tˆ(b))/(b − a))dtˆ(v) for given tˆ(v), respectively,
which are used in the numerical studies for better finite sample approxi-
mations. We denote the upper α-quantiles of these two distributions by c
(2)
a
and c
(2)
m1, respectively.
The test statistic T
(2)
a captures general departures H2a while the test
statistics T
(2)
m1 and T
(2)
m2 are sensitive to the monotone departure H2m. Both
T
(2)
m1 and T
(2)
m2 are expected to be positive when VE(v) decreases as v in-
creases, that is, when H2m holds. Hence the tests T
(2)
a , T
(2)
m1 and T
(2)
m2 reject
H20 if T
(2)
a > c
(2)
a , T
(2)
m1 > c
(2)
m1 and T
(2)
m2 > zα, respectively.
3. Simulation study. In this section, we conduct a simulation study to
check the finite sample performance of the proposed estimation and hypoth-
esis testing procedures using the simple mark-specific proportional hazards
model:
λ(t, v|z) = exp{γv + (α+ βv)z}, t≥ 0,0≤ v ≤ 1,(13)
where α, β and γ are constants and the treatment indicator z takes value
0 or 1 with probability of 0.5 for each value. Under model (13), the mark-
specific baseline function is λ0(t, v) = exp(γv) and VE(v) = 1− exp(α+βv).
The null hypothesis H10 of no vaccine efficacy holds if both α= 0 and β = 0,
and the null hypothesis H20 that vaccine efficacy does not depend on the
type of infecting strain is true if β = 0. Various choices of α and β specify
different alternatives for H10 and H20.
We consider the following simulation models:
(M1) (α,β, γ) = (0,0,0.3), for the null hypothesis H10 of no vaccine efficacy;
(M2) (α,β, γ) = (−0.5,0.5,0.3), as the first alternative of H10;
(M3) (α,β, γ) = (−0.6,0.6,0.3), as the second alternative of H10;
(M4) (α,β, γ) = (−0.6,0,0.3), as the third alternative of H10;
(M5) (α,β, γ) = (−0.69,0,0.3), for the null hypothesis H20 that vaccine ef-
ficacy does not depend on the type of infecting strain;
(M6) (α,β, γ) = (−1.2,1.2,0.3), as the first alternative of H20;
(M7) (α,β, γ) = (−1.5,1.5,0.3), as the second alternative of H20;
(M8) (α,β, γ) = (−1.8,1.8,0.3), as the third alternative of H20.
The models (M2) to (M4) are considered as the alternatives for H1m and
H1a. The departure from H10 :VE(v) = 0 increases as the simulation model
moves from (M2) to (M4). The models (M6) to (M8) are considered as the
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alternatives for H2m and H2a. The departure from H20 increases as the
simulation model moves from (M6) to (M8).
We generate the censoring times from an exponential distribution, inde-
pendent of (T,V ), with the censoring rates ranging from 20% to 30%. We set
the interval of analyses for v as [a, b] = [0.1,0.9] and bandwidths are chosen as
h= 0.05,0.1,0.15. The observed failure times with marks outside the interval
[a, b] can also be used since the smoothing at v takes the cases with marks in
its h-neighborhood. The Epanechnikov kernel K(x) = 0.75(1−x2)I{|x| ≤ 1}
is used throughout. Sample sizes of n= 500 and 800 are studied.
For the tests T
(1)
m2 and T
(2)
m2 , we take the grid of eight evenly spaced points
in [a, b] from 0.196 to 0.868. Table 1 lists the empirical sizes and powers of
the test statistics T
(1)
a , T
(1)
m1 and T
(1)
m2 and Table 2 for the test statistics T
(2)
a ,
T
(2)
m1 and T
(2)
m2 . The significance levels of these tests are given at α = 0.05.
Both tables also list the coverage probabilities of the 95% simultaneous
confidence intervals for CV(v), for v ∈ [a, b] and for v in the grid. The critical
values for the tests T
(1)
m2 and T
(2)
m2 at nominal level 0.05 are zα = 1.645. The
critical values for the tests T
(1)
a and T
(2)
a , T
(1)
m1 and T
(2)
m1 are obtained by
generating 10,000 Wiener processes W (·) with time parameter equal to tˆ(v)
and calculating the corresponding functionals ofW (tˆ(v)), as described in the
previous section. Each entry in Tables 1 and 2 is based on 1000 repetitions.
Most tests have appropriate sizes close to 5%. The test T
(2)
a seems to be
conservative for the simulation models used in the study. The test T
(1)
m1 has
better power than the tests T
(1)
a and T
(1)
m2 . The test T
(2)
m1 has better power
than the tests T
(2)
a and T
(2)
m2 . Therefore the tests that incorporate ĈV(v) over
the entire range [a, b] present greater power than the simpler tests based on
ĈV(v) over the grid. We also observed that the powers of the tests seem to
be influenced by the selection of bandwidth, with greater power for a larger
bandwidth. Similar plots (not included here) to Figure 1 and Figure 2 but
with larger bandwidth h = 0.2 show that the estimated standard errors of
ĈV(v) become smaller for larger h while the biases stay approximately the
same, resulting in increased power for the larger bandwidth. We suspect that
this phenomenon is associated with the sample size and the convergence rate
of the normalized ĈV(v) to a Wiener process. The dependence of the power
on the bandwidth should become small as the sample size increases. Further
study on the bandwidth selection is warranted.
The coverage probabilities of the simultaneous confidence intervals for
CV(v) are closer to the 95% nominal level for v on the grid than on [a, b].
This may be explained by the fact that the convergence for v over the entire
range [a, b] is slower than the convergence on the grid. The evaluations of
the proposed estimators for β(v), VE(v) and CV(v) and their respective
estimators of the standard deviations under some of the simulation models
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Table 1
Empirical sizes and powers of the tests T
(1)
a , T
(1)
m1 and T
(1)
m2 at the nominal level 0.05, and
coverage probabilities of the 95% simultaneous confidence intervals for CV(v) with v on
the grid and on [a, b]
Size/Power Coverage
Model (α,β, γ) n h T
(1)
a T
(1)
m1 T
(1)
m2 Grid [a, b]
M1 (0,0,0.3) 500 0.05 2.9 3.1 7.8 97.5 98.1
0.1 4.9 5.9 8.3 96.6 97.4
0.15 5.1 6.9 7.3 96.2 96.8
800 0.05 5.3 2.8 6.9 95.9 96.8
0.1 5.7 4.7 6.8 95.5 97.0
0.15 5.8 5.2 6.3 95.6 96.5
M2 (−0.5,0.5,0.3) 500 0.05 45.4 56.3 63.2 97.6 98.0
0.1 60.3 71.4 65.7 97.0 97.5
0.15 66.0 77.4 65.5 96.7 97.6
800 0.05 69.1 78.4 77.5 96.1 96.8
0.1 80.3 86.5 80.1 95.6 96.7
0.15 82.9 89.1 80.1 96.0 97.2
M3 (−0.6,0.6,0.3) 500 0.05 59.7 70.0 76.5 97.5 98.0
0.1 75.4 83.9 78.8 96.9 97.8
0.15 80.9 87.2 78.5 96.9 97.9
800 0.05 83.7 90.4 87.6 96.2 96.9
0.1 90.8 94.4 89.6 96.0 96.8
0.15 93.0 96.0 89.6 96.2 97.2
M4 (−0.6,0,0.3) 500 0.05 96.0 95.6 99.9 97.0 97.8
0.1 99.1 98.8 100 96.7 97.6
0.15 99.5 99.7 100 96.7 97.4
800 0.05 99.9 99.5 100 97.0 98.0
0.1 100 100 100 96.9 97.3
0.15 100 100 100 96.4 97.4
are presented in Figure 1 and Figure 2. The plots of the pointwise coverage
probabilities for VE(v) and for CV(v) are given in Figure 3. These plots are
based on n= 500 and h= 0.1.
Now we demonstrate with a simulation example that the adoption of a
standard method for testing the vaccine efficacy that ignores the mark is
inefficient and can be misleading. We consider a special case of the model
discussed in the Introduction, with λ(t, v|z = 0) = 1 and λ(t, v|z = 1) = 2v,
for t≥ 0, 0 ≤ v ≤ 1. The covariate z is again a treatment indicator taking
values 0 and 1 with probability of 0.5 for each value. The marginal hazards
model ignoring the mark is therefore λ(t|z = 0) = 1 and λ(t|z = 1) = 1, for
t ≥ 0. The rest of the simulation setup such as the percentage of censor-
ship, the kernel function and the bandwidth is the same as for the previous
models. The model considered here represents both a proportional mark-
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Fig. 1. Plots of estimates for β(v), VE(v) and CV(v) under the models M1, M2, M5 and M6 for n= 500, h= 0.1. The solid dark lines
are the true functions and the dashed lines are the averages of the estimates based on 1000 repetitions. The gray lines are the corresponding
estimates for β(v), VE(v) and CV(v) of 50 random samples.
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Fig. 2. Plots of the standard errors under the models M1, M2, M5 and M6, based on n= 500, h= 0.1. The solid lines are the averages
of the estimates of the standard deviations of βˆ(v), V̂E(v) and ĈV(v), while the dashed lines are the sample standard deviations of βˆ(v),
V̂E(v) and ĈV(v), based on 1000 repetitions. The gray lines are the corresponding estimates for the standard deviations of βˆ(v), V̂E(v)
and ĈV(v) of 50 random samples.
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Table 2
Empirical sizes and powers of the tests T
(2)
a , T
(2)
m1 and T
(2)
m2 at the nominal level 0.05, and
coverage probabilities of the 95% simultaneous confidence intervals for CV(v) with v on
the grid and on [a, b]
Size/Power Coverage
Model (α,β, γ) n h T
(2)
a T
(2)
m1 T
(2)
m2 Grid [a, b]
M5 (−0.69,0,0.3) 500 0.05 1.6 3.7 3.7 97.0 97.8
0.1 2.1 3.7 4.5 96.5 97.5
0.15 2.1 3.5 4.6 96.8 97.3
800 0.05 2.3 4.0 2.9 97.3 98.3
0.1 2.6 4.3 3.2 97.0 97.6
0.15 2.1 3.5 3.0 96.9 97.4
M6 (−1.2,1.2,0.3) 500 0.05 47.2 67.6 47.7 97.9 98.5
0.1 60.2 76.7 62.3 97.1 97.6
0.15 63.2 80.3 73.3 97.5 97.8
800 0.05 69.2 85.1 69.2 96.5 97.2
0.1 80.4 92.0 80.4 96.6 97.6
0.15 84.2 94.1 88.4 96.9 97.8
M7 (−1.5,1.5,0.3) 500 0.05 63.8 81.4 62.1 97.7 98.0
0.1 76.9 78.0 63.6 97.2 98.0
0.15 81.2 91.7 86.3 97.6 98.0
800 0.05 85.1 94.4 82.6 96.2 97.1
0.1 93.2 98.2 91.8 96.1 97.6
0.15 96.0 98.9 97.4 96.7 97.7
M8 (−1.8,1.8,0.3) 500 0.05 77.6 89.1 73.6 97.8 98.5
0.1 87.1 95.6 85.7 97.3 98.4
0.15 91.5 96.9 92.8 97.7 98.7
800 0.05 93.5 98.2 91.4 96.4 97.4
0.1 98.2 99.5 97.0 96.3 97.5
0.15 99.3 99.9 99.2 96.5 97.9
specific hazards model for λ(t, v|z) and a proportional hazards model for
λ(t|z) = λ0(t) exp(βz), with the mark-specific vaccine efficacy VE(v) = 1−2v
and the marginal VE = 1− exp(β) = 0. The standard Wald test, denoted by
Tw, under the marginal Cox model is often used to test for the vaccine effi-
cacy. As expected, the standard Wald test shows no power (Table 3). It is
incapable of revealing any vaccine efficacy or that the vaccine efficacy de-
pends on the mark, thus missing the important scientific finding that the
vaccine protects against viruses with smaller mark values (V < 0.5) and
increases risk of infection with viruses with larger mark values (V > 0.5).
The example we constructed here shows the weakness of using the standard
approach that ignores the mark and is what motivates the present research.
4. Application. The first preventive HIV vaccine efficacy trial was car-
ried out in North America and The Netherlands, and enrolled 5403 HIV-
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Fig. 3. Plots of the pointwise coverage probabilities for VE(v) (gray lines) and for CV(v)
(solid lines), based on n= 500, h= 0.1 and 1000 repetitions. The models on the left panel
are M1, M2 and M3. The models on the right panel are M5, M6 and M7.
negative volunteers at risk for acquiring HIV infection [4]. Volunteers were
randomized in a 2:1 ratio to receive a recombinant glycoprotein 120 vac-
cine (AIDSVAX) or placebo, and were monitored for HIV infection at semi-
annual HIV testing visits for 36 months. The primary objective was to assess
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Table 3
Comparison of the standard Wald test with the proposed tests T
(1)
a , T
(1)
m1 , T
(1)
m2 , T
(2)
a , T
(2)
m1
and T
(2)
m2 at the nominal level 0.05
Power
n h Tw T
(1)
a T
(1)
m1 T
(1)
m2 T
(2)
a T
(2)
m1 T
(2)
m2
500 0.05 5.9 14.9 24.2 16.6 98.0 99.4 97.3
0.1 − 23.9 35.7 16.0 99.6 100 99.8
0.15 − 27.9 39.1 15.7 99.9 100 99.9
800 0.05 6.1 32.4 39.6 15.0 100 100 99.6
0.1 − 43.1 51.5 13.8 100 100 100
0.15 − 46.0 53.3 13.9 100 100 100
VE using the standard Cox model, and a secondary objective was to test
H10 :VE(t, v) = 0 and H20 : VE(t, v) = VE(t) for three different mark vari-
ables V defined in terms of the percent mismatch of aligned amino acid
sequences (for each infecting HIV sequence compared to the HIV sequence
[named GNE8] contained in the AIDSVAX construct) in three subregions of
HIV-gp120. For brevity, in this article we consider only one mark V , defined
as the percent mismatch of amino acids in the whole gp120 region (581 amino
acids long), where all possible mismatches of particular pairs of amino acids
(e.g., A versus C) are weighted by the estimated probability of interchange
[12]. The distance is based on the gp120 region because this region con-
tains neutralizing epitopes that potentially can induce anti-HIV antibody
responses that prevent HIV infection [21]; the vaccine was designed to pro-
tect by stimulating high titer antibodies that neutralize exposing HIVs. Of
the 368 individuals infected during the trial, 32 had missing marks. Of the
remaining 336 samples, all marks were unique (217 vaccine; 119 placebo).
The vaccine efficacy is estimated and tested by adjusting for two covari-
ates: age (ranging 18–62 years with mean of 36.5) and behavioral risk score
(taking values 0–7) as defined in [4]. It is relevant to adjust for these co-
variates because they predict infection rate and because trial participants
with different values of these covariates may be exposed to HIV strains with
different distributions of V . Both covariates are considered as continuous
variables. The histograms of the rescaled mark values, ages in years and
behavioral risk scores are plotted in Figure 4. We denote the treatment in-
dicator by z1 (z1 = 1 for the vaccine and z1 = 0 for the placebo), age by
z2 and behavioral risk score by z3, and denote the corresponding coefficient
functions by β1(v), β2(v) and β3(v). Fitting model (2) with h = 0.3, the
plots of the estimates for β1(v), β2(v) and β3(v) and their pointwise confi-
dence bands are given in Figure 5. The plots of V̂E(v) and ĈV(v) with their
corresponding pointwise confidence bands adjusting for the two covariates
z2 and z3 are given in Figure 6.
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Adjusting for age and behavioral risk score, the Wald test statistic for test-
ing the marginal VE = 0 using the standard Cox model is −0.978, yielding
a p-value of 0.328 for the two-sided alternative and 0.164 for the monotone
alternative. Our test with the test statistic T
(1)
a for H10 :VE(v) = 0 for all v
versus the general alternative H1a yields a p-value of 0.1532. The p-values
for testing against the monotone alternative H1m are 0.0916 for T
(1)
m1 and
0.0228 for T
(1)
m2 . These results give some, albeit weak, evidence of nonzero
vaccine efficacy for at least one mark value; see Figure 6.
In addition, adjusting for age and behavioral risk score, we conducted
the tests to evaluate whether the vaccine efficacy varies with the mark. The
p-value for testing H20 that VE(v) does not depend on v versus the general
alternative H2a is 0.2067 for the test statistic T
(2)
a . The p-value for testing
for the monotone alternative H2m is 0.9363 for the test statistic T
(2)
m1 and
0.9047 for the test statistic T
(2)
m2 . These p-values are expected given the plots
in Figure 6 where V̂E(v) shows some tendency to increase with v.
5. Discussion. This article developed inference techniques for the pro-
portional hazards model with a continuous mark variable, including non-
parametric methods for estimation and testing of mark-specific regression
functions. These techniques can be used to estimate mark-specific vaccine
efficacy (VE(v)) and cumulative mark-specific vaccine efficacy (CV(v)) with
simultaneous confidence bands, and to test hypotheses for VE(v), while ad-
justing for time-dependent covariate effects. The testing procedures based
on the statistics T
(1)
m1 and T
(2)
m2 showed greatest power in simulations and are
recommended for testing VE(v) = 0 for all v and for testing VE(v) indepen-
dent of v, respectively.
An alternative approach to the continuous mark-specific PH model would
be a similar model that treats the mark variable as ordinal categorical. We
focused on a continuous mark because (i) it most naturally suits the HIV
vaccine application, as the choice of K bins for categorizing the marks would
be arbitrary and (ii) testing β(v) = β can often be done with greater power
than testing equality of the cause-specific regression coefficients β1 = · · ·=
βK .
As is well known for a discrete mark-specific hazard function, the interpre-
tation of the continuous mark-specific hazard function λ(t, v) is restricted to
actual study conditions, that is, it is the instantaneous rate of failure in the
presence of all of the circulating competing risks (i.e., is a “crude” hazard
in the terminology of Prentice et al. [14]). However, often the main scientific
interest is in the “net” mark-specific hazard, the instantaneous rate of failure
by mark v in the absence of any other competing risks, but unfortunately
this parameter is not identified except under untestable assumptions such
M
A
R
K
-S
P
E
C
IF
IC
P
R
O
P
O
R
T
IO
N
A
L
H
A
Z
A
R
D
S
M
O
D
E
L
S
2
1
Fig. 4. Histograms for the observed mark values, ages in years and behavioral risk scores. The left panel is for the vaccine group and
the right panel is for the placebo group.
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Fig. 5. Plots of the estimated regression coefficients β1(v), β2(v) and β3(v) and their
95% pointwise confidence bands for the vaccine trial data with h= 0.3.
as mutual independence of all of the notional (latent) mark-specific failure
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Fig. 6. Plots of the estimates of VE(v) and CV(v) and their confidence bands for the
vaccine trial data with h= 0.3. The dashed lines are 95% pointwise confidence bands and
the dotted lines are 95% simultaneous confidence bands.
times [18]. This problem necessitates careful interpretation of inferences in
the mark-specific PH model.
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For the HIV vaccine trial example, the crude mark-specific hazard can be
factored as
λ(t, v|z) = λE(t, v|z)× λPC(t|v, z)(14)
where λE(t, v|z) is the intensity of exposure to strain v for participants with
covariates z and λPC(t|v, z) (the “per-contact” transmission hazard) is the
same as λ(t, v|z) except that it further conditions on the (unobserved) pres-
ence of exposure to a virus with genetic distance v during [t, t+dt). Exposure
can arise from unprotected sex or sharing a needle with an individual in-
fected with strain v. Therefore the identified parameter measures a mixture
of vaccine/placebo-group differences in mark-specific exposure rates and in
conditional mark-specific per-exposure transmission probabilities, whereas
biological interest is in
VEPC(t|v, z2) = 1− λPC(t|v,1, z2)
λPC(t|v,0, z2)
as a measure of vaccine efficacy. However, as data are not available for esti-
mating the relative intensity λE(t, v|1, z2)/λE(t, v|0, z2), our approach is to
use
VE(t, v|z2) = 1− λ(t, v|1, z2)
λ(t, v|0, z2)
as the target estimand, and assume identical exposure rates between the
two groups, so this target has the same interpretation as VEPC(t|v, z2).
Reliance on this assumption demonstrates the value of including covariates
z2 that predict mark-specific exposure into the mark-specific PH model: the
richer the covariate information the more likely VE(t, v|z2) reflects biological
vaccine efficacy. Gilbert, McKeague and Sun [5] provided further discussion
of the interpretation of mark-specific hazard ratios.
The usefulness of our approach relies on the validity of the mark-specific
proportional hazards model. Lin, Wei and Ying [9] developed goodness-of-
fit tests for the standard Cox model based on martingale residuals, and
their tests can be extended to the present setting by using the mark-specific
martingale residuals
Mˆi(t, v) =
∫ t
0
∫ v
a
[Ni(ds, du)− Yi(s) exp((βˆ(u))TZi)Λˆ0(ds, du)],(15)
for i= 1, . . . , n. These residuals may be interpreted as the difference at time
t between the observed and the predicted number of events with mark less
than v for the ith subject, and are informative about model misspecification.
It can be checked that n−1/2
∑n
i=1 Mˆi(t, v) = op(1). This property is similar
to that in the standard Cox model, where the sum of the martingale residuals
is exactly zero. The difference here is caused by the kernel smoothing in a
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neighborhood of v. Because β(v) is treated nonparametrically, the checking
of the model (2) needs further development and has additional issues related
to the bandwidth. This would need a thorough treatment that is beyond the
scope of the present paper.
Finally, we caution that the method proposed here requires large sample
sizes to work well as demonstrated in the simulation study. This is the result
of β(v) being treated nonparametrically: the estimation of β(v) utilizes only
the observed failures with marks in a neighborhood of v. Although this does
not cause a problem in our application to the first preventive HIV vaccine
trial (which has a sample size of 5403), one needs to be careful in applying
the method to situations with small sample sizes.
APPENDIX
The following lemma is an extension of Theorem 5.7 of van der Vaart [19]
and will be used to prove the uniform consistency of βˆ(v).
Lemma A.1. Let Qn(v, θ) be random functions and let Q(v, θ) be a fixed
function of (v, θ) ∈ [a, b] × Θ, Θ ⊂ Rp. Let β(v) be a fixed function of v ∈
[a, b] taking values in Θ. Assume that supv,θ |Qn(v, θ) −Q(v, θ)| P−→ 0 and
that for every ε > 0 there exists an η > 0 such that sup‖θ−β(v)‖>εQ(v, θ)<
Q(v,β(v))− η for v ∈ [a, b]. Then for any sequence of estimators βˆ(v), with
Qn(v, βˆ(v)) >Qn(v,β(v)) − op(1) uniformly in v ∈ [a, b], we have βˆ(v) P−→
β(v) uniformly in v ∈ [a, b].
Proof. For every ε > 0, there exists an η > 0 such that{
sup
v
‖βˆ(v)− β(v)‖> ε
}
⊂
⋃
v
{‖βˆ(v)− β(v)‖> ε}
⊂
⋃
v
{Q(v, βˆ(v))<Q(v,β(v))− η}.
SinceQn(v, βˆ(v))>Qn(v,β(v))−op(1) P−→Q(v,β(v)), uniformly in v ∈ [a, b],
we have Qn(v, βˆ(v)) >Q(v,β(v)) − op(1), uniformly in v ∈ [a, b]. It follows
that ⋃
v
{Q(v, βˆ(v))<Q(v,β(v))− η}
⊂
⋃
v
{Q(v, βˆ(v))<Qn(v, βˆ(v))− η + op(1)}
=
{
inf
v
(Q(v, βˆ(v))−Qn(v, βˆ(v)))<−η+ op(1)
}
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=
{
sup
v
(Qn(v, βˆ(v))−Q(v, βˆ(v)))> η− op(1)
}
⊂
{
sup
v
|Qn(v, βˆ(v))−Q(v, βˆ(v))|> η− op(1)
}
,
whose probability goes to 0 by the uniform convergence of Qn(v, θ) to
Q(v, θ). Hence P{supv ‖βˆ(v)− β(v)‖> ε}→ 0. 
The following lemma is used to prove Theorems 3 and 4. Let N =
∑n
i=1Ni
and M =
∑n
i=1Mi.
Lemma A.2. Under conditions (A.1)–(A.4), n−1N(t, v)
P−→ ENi(t, v),
uniformly in (t, u) ∈ [0, τ ] × [0,1], and n−1/2M(t, v) converges weakly to a
mean-zero continuous Gaussian random field G(t, v), (t, v) ∈ [0, τ ] × [0,1],
with independent increments and Var(G(t, v)) =
∫ t
0
∫ v
0 λ0(s,u)s
(0)(s, β(u))dsdu.
Proof. We treat ωi = (Xi, δi, Vi), i= 1, . . . , n, as a random sample from
a probability distribution P on a measurable space (X ,A), with X = [0,∞)×
{0,1} × [0,1] and A its Borel σ-field. Let F be the class of all indicator
functions ft,v :X −→R, where ft,v(ωi) = I([0, t]×{1}× [0, v])(ωi) = I(Xi ≤ t,
δi = 1, Vi ≤ v), for 0≤ t≤ τ,0≤ v ≤ 1. Then n−1N(t, v) = n−1
∑n
i=1 ft,v(ωi).
Let ‖ft,v‖P,r = (P |ft,v|r)1/r be Lr(P )-norm of ft,v.
Let 0 = t0 < t1 < · · · < tK = τ and 0 = v0 < v1 < · · · < vJ = 1 be parti-
tions of the intervals [0, τ ] and [0,1]. Define the bracketing functions lkj =
Ni(tk−1, vj−1) and ukj =Ni(tk, vj), for k = 1, . . . ,K, j = 1, . . . , J . Then for
any ft,v ∈ F , there is a bracket [lkj , ukj] such that ft,v ∈ [lkj, ukj]. And
‖ukj − lkj‖P,1 ≤ E(Ni(tk, vj)−Ni(tk−1, vj−1))
=
∫ tk
0
∫ vj
0
λ0(s,x)s
(0)(s, β(x))dsdx
−
∫ tk−1
0
∫ vj−1
0
λ0(s,x)s
(0)(s, β(x))dsdx
≤
∫ tk
tk−1
∫ 1
0
λ0(s,x)s
(0)(s, β(x))dsdx
+
∫ τ
0
∫ vj
vj−1
λ0(s,x)s
(0)(s, β(x))dsdx
≤ C1(tk − tk−1) +C2(vj − vj−1),
where C1 and C2 are some positive constants. For any ε > 0, choose the grid
points such that tk− tk−1 < ε and vj − vj−1 < ε. Then ‖ukj − lkj‖P,1 ≤ [C1+
C2]ε. Hence, the bracketing number N[·](ε,F ,L1(P )) is of the polynomial
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order (1/ε)2. By the Glivenko–Cantelli theorem (Theorem 19.4 of van der
Vaart [19]), n−1N(t, v)
P−→ENi(t, v), uniformly in (t, v) ∈ [0, τ ]× [0,1].
Next, consider the processes {Mi(t, v),0≤ t≤ τ,0≤ v ≤ 1}, i= 1, . . . , n, as
a random sample from a probability distribution P on a measurable space
(X ,A). Let F be the class of coordinate projections ft,v :X −→ R, where
ft,v(Mi) =Mi(t, v), for 0 ≤ t ≤ τ,0 ≤ v ≤ 1. The process {Mi(t, v),0 ≤ t ≤
τ,0≤ v ≤ 1} is determined by the {Xi, δi, δiVi,Zi}.
Again, let 0 = t0 < t1 < · · ·< tK = τ and 0 = v0 < v1 < · · ·< vJ = 1 be the
partitions of the intervals [0, τ ] and [0,1]. Define the bracketing functions
lkj = Ni(tk−1, vj−1) −
∫ tk
0
∫ vj
0 Yi(s)λ(s,x|Zi(s))dsdx and ukj = Ni(tk, vj) −∫ tk−1
0
∫ vj−1
0 Yi(s)λ(s,x|Zi(s))dsdx, for k = 1, . . . ,K, j = 1, . . . , J . Then for
any ft,v ∈ F , there is a bracket [lkj , ukj] such that ft,v ∈ [lkj , ukj]. The bracket
size is
‖ukj − lkj‖P,2 ≤ ‖Ni(tk, vj)−Ni(tk−1, vj−1)‖P,2
+
∥∥∥∥∫ tk
0
∫ vj
0
Yi(s)λ(s,x|Zi(s))dsdx
−
∫ tk−1
0
∫ vj−1
0
Yi(s)λ(s,x|Zi(s))dsdx
∥∥∥∥
P,2
≤ [C1(tk − tk−1) +C2(vj − vj−1)]1/2,
where C1 and C2 are some positive constants. For any ε > 0, choose the
grid points such that tk − tk−1 < ε and vj − vj−1 < ε. Then ‖ukj − lkj‖P,2 ≤
[C1+C2]
1/2ε1/2. Hence, the bracketing number N[·](ε
1/2,F ,L2(P )) is of the
polynomial order (1/ε)2. Thus, N[·](ε,F ,L2(P )) is of the polynomial order
(1/ε)4 . So the bracketing integral J[·](1,F ,L2(P ))<∞. By the Donsker the-
orem (Theorem 19.5 of van der Vaart [19]), n−1/2M = {n−1/2∑ni=1Mi(t, v),0≤
t≤ τ,0≤ v ≤ 1} converges weakly to a mean-zero Gaussian process G(t, v),
(t, v) ∈ [0, τ ]× [0,1], which can be constructed to have continuous paths by
Theorem 18.14 and Lemma 18.15 of van der Vaart [19].
Now we show that G(t, v) has independent increments. Note that for
t1 ≤ t2 and v1 ≤ v2, the covariance of G(t1, v1) and G(t2, v2) − G(t1, v1)
is E{Mi(t1, v1) × (Mi(t2, v2) − Mi(t1, v1))}. By Aalan and Johansen [1],
Mi(t, v1) and Mi(t, v2) −Mi(t, v1), 0 ≤ t ≤ τ , are orthogonal square inte-
grable martingales for 0≤ v1 ≤ v2 ≤ 1. It follows that
E{Mi(t1, v1)(Mi(t2, v2)−Mi(t1, v1))}
=E{Mi(t1, v1)(Mi(t2, v2)−Mi(t2, v1))}
+E{Mi(t1, v1)(Mi(t2, v1)−Mi(t1, v1))}
= 0.
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Hence G(t1, v1) and G(t2, v2)−G(t1, v1) are independent. 
Proof of Theorem 1. It is easy to check that the conditions of Lemma
1 of Sun and Wu [17] are satisfied under Condition A. It follows that W˜A(v)
converges weakly to a vector of continuous mean-zero Gaussian random pro-
cesses, WA(v), v ∈ [a, b]. Now we show that WA(v) has independent incre-
ments. Let wi(t, v) =
∫ v
a
∫ t
0 A(u)[Zi(t)− s(1)(t, β(u))/s(0)(t, β(u))]Mi(dt, du).
Then W˜A(v) = n
−1/2∑n
i=1wi(τ, v). For a≤ v1 ≤ v2 ≤ b, the covariance ma-
trix of WA(v1) and WA(v2) −WA(v1) is equal to E{wi(τ, v1)(wi(τ, v2) −
wi(τ, v1))
T }. Since Mi(t, v1) and Mi(t, v2)−Mi(t, v1), 0≤ t≤ τ , are orthog-
onal square integrable martingales, it follows that wi(t, v1) and wi(t, v2)−
wi(t, v1), 0 ≤ t ≤ τ , are orthogonal square integrable martingales. Hence
E{wi(τ, v1)(wi(τ, v2)− wi(τ, v1))T } = 0. So WA(v), v ∈ [a, b], is a vector of
mean-zero Gaussian random processes with independent increments.
Further, the covariance matrix of WA(v) is
E{wi(τ, v)(wi(τ, v))T }
=E
{∫ v
a
∫ τ
0
A(u)
[
Zi(t)− s
(1)(t, β(u))
s(0)(t, β(u))
]⊗2
A(u)Ni(dt, du)
}
=E
{∫ v
a
∫ τ
0
A(u)
[
Zi(t)− s
(1)(t, β(u))
s(0)(t, β(u))
]⊗2
×A(u)y(t|Zi(t))λ(t, u|Zi(t))dt du
}
=
∫ v
a
A(u)E
{∫ τ
0
[
Zi(t)− s
(1)(t, β(u))
s(0)(t, β(u))
]⊗2
y(t|Zi(t))λ(t, u|Zi(t))dt
}
×A(u)du
=
∫ v
a
A(u)Σ(u)A(u)du.
This completes the proof of Theorem 1. 
Proof of Theorem 2. We shall prove Theorem 2 by verifying the
conditions of Lemma A.1.
Let
ηn(u, θ) = n
−1
n∑
i=1
∫ u
0
∫ τ
0
[θTZi(t)− log(S(0)(t, θ))]Ni(dt, du),
ξn(u, θ) = n
−1
n∑
i=1
∫ u
0
∫ τ
0
[θTZi(t)− log(s(0)(t, θ))]Ni(dt, du),
Qn(v, θ) = n
−1l(v, θ) + n−1 logn
∫ 1
0
Kh(u− v)N(τ, du).
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Then by Condition A, ηn(v, θ) = ξn(v, θ) +Op(n
−1/2) and
Qn(v, θ) =
∫ 1
0
Kh(u− v)ηn(du, θ)
=
∫ 1
0
Kh(u− v)ξn(du, θ) +Op(n−1/2h−1),
uniformly in (v, θ) ∈ [0,1] × [−M,M ], for M > 0. By application of the
Glivenko–Cantelli and Donsker theorems, similarly to the proofs of Lemma
A.2 and Theorem 1, ξn(v, θ) = ξ(v, θ) + Op(n
−1/2), uniformly in (v, θ) ∈
[0,1]× [−M,M ], with
ξ(v, θ) =E
[∫ u
0
∫ τ
0
[θTZi(t)− log(s(0)(t, θ))]Ni(dt, du)
]
.
It follows that Qn(v, θ) =Q(v, θ)+Op(n
−1/2h−1), uniformly in (v, θ) ∈ [a, b]×
[−M,M ], where
Q(v, θ) =E
[∫ τ
0
[θTZi(t)− log(s(0)(t, θ))]λ0(t, v) exp(βT (v)Zi(t))Yi(t)dt
]
.
Now we show that β(v) is the well-separated point of maximum of Q(v, θ)
for v ∈ [0,1]. Note that
∂Q(v, θ)/∂θ =E
[∫ τ
0
[
Zi(t)− s
(1)(t, θ)
s(0)(t, θ)
]
λ0(t, v) exp(β
T (v)Zi(t))Yi(t)dt
]
∂2Q(v, θ)/∂θ2 =−E
[∫ τ
0
{
s(2)(t, θ)
s(0)(t, θ)
−
(
s(1)(t, θ)
s(0)(t, θ)
)⊗2}
× λ0(t, v) exp(βT (v)Zi(t))Yi(t)dt
]
.
We have ∂Q(v,β(v))/∂θ = 0, and for every ε > 0 there exists an η > 0
such that sup‖θ−β(v)‖>εQ(v, θ) < Q(v,β(v)) − η for v ∈ [a, b], under condi-
tion (A.3), by Taylor expansion and continuity. Further, since Qn(v, θ)
P−→
Q(v, θ), ∂Qn(v, θ)/∂θ
P−→ ∂Q(v, θ)/∂θ, and ∂2Qn(v, θ)/∂θ2 P−→ ∂2Q(v, θ)/
∂θ2 uniformly in (v, θ) ∈ [a, b]× [−M,M ], and −M˜ < β(v)< M˜ for a≤ v ≤ b
for some M˜ < M , we have for every α > 0 there exists an n0 such that
P (−M ≤ βˆ(v)≤M,a≤ v ≤ b)> 1− α for n≥ n0.
Therefore, for every ε > 0,
P
(
sup
a≤v≤b
‖βˆ(v)− β(v)‖> ε
)
≤ α+P
(
sup
a≤v≤b
‖βˆ(v)− β(v)‖> ε,−M ≤ βˆ(v)≤M,a≤ v ≤ b
)
→ α
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as n→∞, by the previous checking of the conditions of Lemma A.1 together
with Qn(v, βˆ(v))≥Qn(v,β(v)). Since α is arbitrary, we have P (supa≤v≤b ‖βˆ(v)−
β(v)‖> ε)→ 0. 
Proof of Theorem 3. In the proof of this theorem, we set β = β(v)
for simplicity. Note that under Condition A, using a second-order Taylor
expansion for λ(t, u|Zi(t)) in the neighborhood of v, we have
n−1/2
∣∣∣∣∣
n∑
i=1
∫ 1
0
∫ τ
0
Kh(u− v)
[
Zi(t)− S
(1)(t, β)
S(0)(t, β)
]
Yi(t)
× [λ(t, v|Zi(t))− λ(t, u|Zi(t))]dt du
∣∣∣∣∣
=Op(n
1/2h2),
uniformly in v ∈ [0,1]. It follows that
n−1/2U(v,β) = n−1/2
n∑
i=1
∫ 1
0
∫ τ
0
Kh(u− v)
[
Zi(t)− S
(1)(t, β)
S(0)(t, β)
]
× [Ni(dt, du)− Yi(t)λ(t, v|Zi(t))dt du]
= n−1/2
n∑
i=1
∫ 1
0
∫ τ
0
Kh(u− v)
[
Zi(t)− S
(1)(t, β)
S(0)(t, β)
]
Mi(dt, du)
+Op(n
1/2h2),
uniformly in v ∈ [0,1].
Next, we show that for each v, n−1/2h1/2U(v,β) converges weakly to
a normal distribution. By Lemma A.2, n−1/2M(t, v) converges weakly to
a mean-zero Gaussian process. By Condition A, ‖S(j)(t, β) − s(j)(t, β)‖ =
op(n
−1/2+δ), uniformly in t for j = 0,1, for 0< δ < 1/2. Note that n−1/2+δh−1/2 =
o(1) for δ = 1/4 as nh2→∞. We have h1/2Kh(u− v)‖S(j)(t, β)− s(j)(t, β)‖
goes in probability to zero. Applying Lemma 2 of Gilbert, McKeague and
Sun [5], we have
n−1/2h1/2U(β(v))
= n−1/2h1/2
n∑
i=1
∫ 1
0
∫ τ
0
Kh(u− v)
[
Zi(t)− s
(1)(t, β)
s(0)(t, β)
]
×Mi(dt, du) +Op(n1/2h5/2) + op(1)
(16)
= n−1/2h1/2
n∑
i=1
∫ 1
0
∫ τ
0
Kh(u− v)
[
Zi(t)− s
(1)(t, β(u))
s(0)(t, β(u))
]
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×Mi(dt, du) +Op(n1/2h5/2) + op(1)
= h1/2
∫ 1
0
Kh(u− v)W˜I(du) +Op(n1/2h5/2) + op(1),
where W˜I(v) is defined in (6) with A= I and a= 0.
Since W˜I(v)
D−→WI(v) by Theorem 1, by the almost sure representa-
tion theorem ([16], page 47), there exist W˜ ∗I (v) and W
∗
I (v) on some prob-
ability space that have the same distributions and sample paths as W˜I(v)
and WI(v), respectively, such that W˜
∗
I (v)
a.s.−→W ∗I (v) uniformly in v ∈ [0,1].
Hence
∫ 1
0 Kh(u− v)W˜ ∗I (du) =
∫ 1
0 Kh(u− v)W ∗I (du)+Op(n−1/2h−1) by inte-
gration by parts since K(·) has bounded variation. It follows that
h1/2
∫ 1
0
Kh(u− v)W˜I(du) D= h1/2
∫ 1
0
Kh(u− v)W˜ ∗I (du)
= h1/2
∫ 1
0
Kh(u− v)W ∗I (du) +Op(n−1/2h−1/2).
Since W ∗I (v) is a Gaussian martingale with covariance matrix of
∫ v
0 Σ(u)du,
and h1/2
∫ 1
0 Kh(u− v)W ∗I (du) is a mean-zero Gaussian random vector with
covariance matrix equal to h
∫ 1
0 K
2
h(u−v)Σ(u)du→ ν0Σ(v) as h→ 0. Hence,
h1/2
∫ 1
0 Kh(u−v)W˜I(du) D−→N(0, ν0Σ(v)) as h→ 0, nh→∞. By the Slutsky
theorem, n−1/2h1/2U(v,β) converges weakly to N(0, ν0Σ(v)) as nh
2 →∞
and nh5→ 0.
Note that U(βˆ(v))− U(β(v)) = l′′β(v,β∗(v))(βˆ(v)− β(v)), where β∗(v) is
on the line segment between βˆ(v) and β(v). By Condition A and the uniform
consistency of βˆ(v) on v ∈ [a, b]⊂ (0,1), we have n−1l′′β(v,β∗(v)) =−Σ(v) +
op(1), uniformly in v ∈ [a, b] for 0< δ < 1/2. Hence,
n1/2h1/2(βˆ(v)− β(v)) =−(l′′β(v,β∗(v))/n)−1n−1/2h1/2U(β(v))
(17)
= (Σ(v))−1n−1/2h1/2U(β(v)) + op(1),
uniformly in v ∈ [a, b]. It follows that (nh)1/2(βˆ(v)−β(v)) D−→N(0, ν0Σ(v)−1)
as nh2→∞ and nh5→ 0. 
Proof of Theorem 4. From (16) and the first line of (17), we have,
for v ∈ [a, b],∫ v
a
n1/2(βˆ(u)− β(u))du=−
∫ v
a
(Σ(u))−1
∫ 1
0
Kh(x− u)W˜I(dx)du+ op(1).
Exchanging the order of integration and by the compact support of the
kernel function K(·) on [−1,1], we have∫ v
a
n1/2(βˆ(u)− β(u))du
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=−
∫ 1
0
[∫ v
a
(Σ(u))−1Kh(x− u)du
]
W˜I(dx) + op(1)
=−
∫ v−h
a+h
[∫ v
a
(Σ(u))−1Kh(x− u)du
]
W˜I(dx)(18)
−
∫ a+h
a−h
[∫ v
a
(Σ(u))−1Kh(x− u)du
]
W˜I(dx)
−
∫ v+h
v−h
[∫ v
a
(Σ(u))−1Kh(x− u)du
]
W˜I(dx) + op(1).
By Theorem 1, the process W˜I(x) converges weakly to a mean-zero Gaussian
process with continuous paths. Under the assumption (A.4),
∫ v
a (Σ(u))
−1Kh(x−
u)du has bounded variation and converges uniformly to Σ(x)−1 for x ∈
(a+h, v−h). By Lemma 2 of Gilbert, McKeague and Sun [5], the first term
in (18) is − ∫ va (Σ(x))−1W˜I(dx)+op(1). Similar arguments lead to the second
and the third terms in (18) to be op(1). Hence∫ v
a
n1/2(βˆ(u)− β(u))du=−
∫ v
a
(Σ(x))−1W˜I(dx) + op(1)
=−W˜Σ−1(v) + op(1),
which converges weakly to a p-dimensional mean-zero Gaussian martingale,
WΣ(v)−1(v), with continuous paths. The covariance matrix of WΣ(v)−1(v)
equals to Cov(WΣ−1(v)) =
∫ v
a Σ(u)
−1Σ(u)Σ(u)−1 du=
∫ v
a Σ(u)
−1 du. 
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